Nicole A. Cipriani
Papers
2
Total Citations
57
H-Index
2
About
Nicole A. Cipriani is a leading clinical investigator in head and neck oncology, with a focused expertise in human papillomavirus-positive (HPV+) oropharyngeal cancer. Her research centers on integrating immunotherapy into curative treatment paradigms, particularly through neoadjuvant approaches designed to both enhance efficacy and enable safe, response-adapted de-intensification of therapy. Her major contributions include pioneering the use of neoadjuvant nivolumab plus chemotherapy, followed by response-adaptive treatment, in HPV+ oropharyngeal cancer. This work, published in 2024 and garnering 45 citations, addresses a critical gap: while immune checkpoint inhibitors improve survival in recurrent/metastatic disease, their role in the curative setting was previously undefined. Dr. Cipriani has also advanced the field with the TARGET-HPV trial, evaluating neoadjuvant HB-200, a novel HPV16-specific arenavirus-based immunotherapy, combined with chemotherapy. This study, with 12 citations, leverages the unique biology of HPV16+ tumors, which constitutively express viral epitopes, to drive antigen-specific anti-tumor immunity. Her work is reshaping treatment landscapes, aiming to reduce long-term toxicity without compromising oncologic outcomes.
Research Focus
Key Achievements
Top Papers
- 1
- 2